Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

NeuroSense, Mass General to collaborate on PrimeC in ALS

NeuroSense Therapeutics (NASDAQ:NRSN) signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, Ph.D., and Massachusetts General Hospital’s NeuroEpigenetics lab to explore the neurotherapeutic effects of...

March 27, 2023

Developments

EyePoint completes enrollment in Phase 2 wet AMD trial

EyePoint Pharmaceuticals (NASDAQ:EYPT) completed enrollment in the Phase 2 “Durasert and Vorolanib in Ophthalmology 2” (DAVIO 2) clinical trial evaluating EYP-1901 as a potential six-month maintenance...

March 27, 2023

Developments

Vistagen posts positive Phase 3 open-label study of fasedienol in SAD

Vistagen (NASDAQ:VTGN) reported positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of fasedienol (PH94B) over time in...

March 22, 2023

Developments

Atossa, Quantum Leap in new study arm of I-SPY 2 clinical trial

Atossa Therapeutics (NASDAQ:ATOS) and Quantum Leap Healthcare Collaborative announced that Atossa’s proprietary selective estrogen receptor modulator, (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I...

March 22, 2023

Developments

Hepion to highlight AI-POWR platform at AI webinar

Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...

March 17, 2023

Developments

OpSens in specialty diagnostics pact with Premier for SavvyWire

OpSens (TSX:OPS; OTCQX:OPSSF) was awarded a national group purchasing agreement for interventional specialty diagnostics with Premier, a leading healthcare improvement company uniting an alliance with approximately...

March 14, 2023

Developments

Reneo reaches target enrollment in pivotal trial in primary mitochondrial myopathies

Reneo Pharmaceuticals (NASDAQ:RPHM) achieved its target enrollment of 200 patients in the pivotal STRIDE study of mavodelpar in primary mitochondrial myopathies (PMM). Topline data from the STRIDE study are expected in...

March 14, 2023

Developments

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

LENZ Therapeutics raised $83.5-million in an oversubscribed Series B financing. New investor, Sectoral Asset Management, led the financing and was joined by Alpha Wave Ventures and Point 72, as well as existing...

March 7, 2023

Developments

BioStem to acquire majority of assets of Auxocell Laboratories

BioStem Technologies (OTCQB:BSEM) agreed to acquire the majority of the assets of Auxocell Laboratories, a leading solid tissue processing equipment manufacturer. The Auxocell solid tissue processing device, AC:Px, is a...

March 7, 2023

Developments

Hepion to update rencofilstat Phase 2 programs at NASH Congress

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CMO, Todd Hobbs, M.D., will be presenting, “Rencofilstat (CRV431): Update on NASH Clinical Program,” on March 3 at the 6th Global NASH Congress in London. Dr. Hobbs will be...

March 3, 2023

Developments

Hepion’s rencofilstat IP estate strengthened with new European patent

The European Patent Office granted a patent to Hepion Pharmaceuticals (NASDAQ:HEPA) covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat. The newly granted European patent also...

March 2, 2023

Developments

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

The FDA granted orphan drug designation for Aravive’s (NASDAQ:ARAV) batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). In a statement, Gail McIntyre, Ph.D., DABT, CEO of Aravive, said three...

March 1, 2023

Developments

Atossa doses first patient in Phase 2 breast cancer study

Atossa Therapeutics (NASDAQ:ATOS) dosed the first patient in the Phase 2 EVANGELINE non-inferiority clinical trial of Atossa’s patented selective estrogen receptor modulator, (Z)-endoxifen, and exemestane plus goserelin...

February 23, 2023

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Developments

SenterCare in pact to bring aging-at-home-safely technology to Japan

Closely-held SenterCare, a member of the Trendlines Group of Israel, and Nozomi MedAlliance established an alliance to bring SenterCare’s advanced aging-at-home-safely technology to the Japanese market. SenterCare has...

February 21, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Developments

Freedom Holding to acquire Maxim Group for $400-million

Freedom Holding (NASDAQ:FRHC), a multi-national financial services firm, agreed to acquire Maxim Group and its registered investment advisory affiliate, Maxim Financial Advisors, for a combination of cash and common...

February 17, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Developments

Abbott to acquire Cardiovascular Systems for $890-million

Abbott (NYSE:ABT) agreed to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII) for $20 a share or approximately $890-million. Cardiovascular Systems is a leader in devices for atherectomy, a minimally invasive treatment...

February 9, 2023

Developments

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...

February 8, 2023

Developments

Annovis Bio to expand Phase 3 PD study of buntanetap to EU

Annovis Bio (NYSE:ANVS) received approval to open 48 clinical trial sits in five European Union countries for its ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (PD). The company is...

February 8, 2023

Subscribe